Infant, Newborn, Diseases Clinical Trial
Official title:
Increasing Neonatal HIV Test and Treat to Maximize the Long-Term Impact on Infant Health and Novel Infant Antiretroviral Treatment
This study aims to improve HIV healthcare services for mothers living with HIV and their newborns in Tanzania and Mozambique. The main questions it aims to answer are: 1) does enhancing screening with maternal HIV viral load monitoring at delivery identify more mother-child pairs at high-risk for HIV vertical transmission? and 2) are high-risk infants linked to appropriate prevention and care? The study will expand access to HIV testing services to more rural settings using a hub-and-spoke referral system.
The UN Sustainable Development Goals set the ambitious goal to eliminate new paediatric HIV infections by 2030. Between 2010 and 2020, new HIV infections among children declined by more than 50%. This decline demonstrates the goal is achievable, but the loss of momentum in recent years indicates a need for further improvements. Results from the previous LIFE study conducted in Mozambique and Tanzania demonstrated that identifying HIV-infection in neonates and starting HIV treatment as early as birth is feasible and may reduce infant death and severe disease. However, this study also demonstrated that it is difficult to administer infant HIV treatments due to poor palatability of the infant drug formulation, socio-behavioural constraints for mothers, and care linkage challenges. This resulted in poor treatment adherence and efficacy (as measured by HIV suppression rates in the blood). The investigators propose to expand and optimize treatment and prevention interventions for mothers living with HIV and their newborns and translate previous research findings into policy and practice, with a focus on primary healthcare to reduce access inequities in rural areas. The study aims to scale-up of tools used for vertical HIV transmission risk screening affiliated with immediate, risk-based HIV test & treat procedures. Testing for high-risk case detection will be implemented in a hub-and-spoke model, where smaller, less well-equipped health facilities refer samples to nearby larger health facilities for diagnostic testing, ensuring rural communities have access to the interventions. The investigators will also provide personnel support for scale-up of high-risk case detection and high-risk infant care management. Furthermore, all high-risk mother-baby pairs will receive enhanced counselling services. eHealth tools for electronic result sharing across health facilities will be part of our package of interventions. The investigators will evaluate the impact of the intervention package described above on key prevention of vertical HIV transmission (PVHT) program indicators (e.g., percentage of high-risk newborns immediately tested for HIV, percentage of newborns with HIV immediately started on treatment) in a stepped-wedge, cluster-randomized study. The investigators will also conduct a cost-effectiveness analysis of the intervention package. Furthermore, the investigators will conduct interviews and use self-reported questionnaires by the participants and site staff to better understand the socio-economic and behavioural factors contributing to high-risk classification. For HIV-positive babies, the investigators will assess the impact of a novel HIV drug used for newborns, i.e. Dolutegravir (DTG), on health outcomes. The investigators will also characterize the impact of transmitted and acquired genotypic drug resistance, as well as transmitted viral strains, towards neutralization against established and novel broadly neutralizing antibodies. This information will be used to inform future prevention and treatment strategies for HIV-exposed newborns. All mothers of HIV-positive babies taking part in this study will continue to have access to enhanced counselling and care support throughout the study, and the investigators will collect information on socio-behavioural factors influencing treatment outcomes to understand challenges related to infant HIV treatment. This study will be performed by an established consortium of interdisciplinary African and European experts, closely collaborating with health authorities and policy makers, thus ensuring effective and sustainable implementation, programmatic stewardship, and global access to the proposed complex intervention. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05954975 -
Baby Sickness Evaluation
|
||
Not yet recruiting |
NCT05936112 -
Quantification of Fecal Calprotectin Concentration Difference Between Infants Aged Under 4 Months Old Suffering From Functional Gastrointestinal Disorders (FGID) and Infants Aged Under 4 Months Old Free From Disorders : a Transversal Case-control Monocentric Study
|
N/A | |
Completed |
NCT02968628 -
Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)
|
||
Not yet recruiting |
NCT00994149 -
Diazoxide In the Management Of Hypoglycemic Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT03571932 -
Assessment of Family Planning and Immunization Service Integration in Liberia
|
||
Completed |
NCT02865772 -
Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns
|
N/A | |
Completed |
NCT03535311 -
Estimating Insertion Length of Umbilical Catheters in Newborn Infants
|
||
Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
Recruiting |
NCT06139809 -
Noninvasive Positive Pressure Ventilation During Neonatal Nasal Intubation
|
N/A | |
Recruiting |
NCT03162653 -
Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome
|
Phase 3 | |
Completed |
NCT02701920 -
HeartLight: Heart Rate Monitoring for Newborn Resuscitation
|
||
Completed |
NCT01124331 -
Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis
|
N/A | |
Active, not recruiting |
NCT04354220 -
Capnography Monitoring in Ventilated Children
|
||
Recruiting |
NCT05793723 -
Long-term Respiratory Complications in Infants With Perinatal COVID-19
|
||
Completed |
NCT03404284 -
Assessment of Family Planning and Immunization Service Integration in Malawi
|
N/A | |
Completed |
NCT01954056 -
Hydrocortisone for Term Hypotension
|
Phase 3 | |
Not yet recruiting |
NCT06255886 -
Treatment of Gastroesophageal Reflux Disease in Infants
|
Phase 4 | |
Completed |
NCT02434380 -
Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes
|
Phase 3 | |
Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT00362180 -
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
|
Phase 2 |